Want to see IN:ASTEC full AI Analyst Report?
ASTEC Stock Chart & Stats
₹703.50
-₹43.60(-3.76%)
At close: 4:00 PM EST
₹703.50
-₹43.60(-3.76%)
Day’s Range― - ―
52-Week Range₹512.35 - ₹979.05
Previous CloseN/A
Volume22.45K
Average Volume (3M)412.49K
Market Cap
₹15.90B
Enterprise Value₹21.96B
Total Cash (Recent Filing)₹96.91M
Total Debt (Recent Filing)₹3.67B
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Jul 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-56.86
Shares Outstanding22,282,820
10 Day Avg. Volume47,730
30 Day Avg. Volume412,490
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)2.96
Price to Sales (P/S)2.58
P/FCF Ratio-9.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9.7
Revenue Forecast (FY)₹6.39B
Bulls Say, Bears Say
Bulls Say
Integrated Product Portfolio & Export ExposureAstec’s vertically integrated model—making technical actives, intermediates and finished formulations—creates durable margin and supply advantages versus pure-play formulators. Export market access diversifies demand across geographies, smoothing revenue cycles and supporting multi‑year contracts and capacity utilization.
Top-line RecoveryA sustained revenue rebound provides structural capacity to restore operational leverage: higher volumes can spread fixed manufacturing costs, improve utilization, and give management scope to prioritize return to profitability. If sustained, the recovery can underpin medium‑term earnings normalization.
Substantial Asset And Equity BaseA sizable asset and equity base is a durable strength: it supports manufacturing scale, provides collateral for refinancing, and permits phased investments in production or R&D. This structural resource gives management options to stabilize operations without immediate asset disposals.
Bears Say
Sustained Multi-year LossesThree consecutive years of material losses erode retained earnings and limit the company’s ability to self-fund growth or absorb shocks. Persistent unprofitability risks management distraction, reduces reinvestment capacity, and can force external capital raises that dilute shareholders or increase leverage.
Chronic Negative Cash FlowConsistent free cash flow deficits and a step-down to sharply negative operating cash flow mean the business is not self-sustaining. Over the medium term this necessitates repeated financing, raises funding costs, constrains maintenance capex, and increases the risk of liquidity stress if markets tighten.
Elevated Leverage TrendRising leverage to multi‑turns amplifies financial risk, especially alongside negative profits and cash burn. Higher interest obligations and potential covenant constraints reduce strategic flexibility, increase default risk during downturns, and limit the company’s capacity to pursue opportunistic investments.
Astec Lifesciences Limited News
ASTEC FAQ
What was Astec Lifesciences Limited’s price range in the past 12 months?
Astec Lifesciences Limited lowest stock price was ₹512.35 and its highest was ₹979.05 in the past 12 months.
What is Astec Lifesciences Limited’s market cap?
Astec Lifesciences Limited’s market cap is ₹15.90B.
When is Astec Lifesciences Limited’s upcoming earnings report date?
Astec Lifesciences Limited’s upcoming earnings report date is Jul 29, 2026 which is in 27 days.
How were Astec Lifesciences Limited’s earnings last quarter?
Astec Lifesciences Limited released its earnings results on Apr 27, 2026. The company reported -₹3.5 earnings per share for the quarter, missing the consensus estimate of ₹0.5 by -₹4.
Is Astec Lifesciences Limited overvalued?
According to Wall Street analysts Astec Lifesciences Limited’s price is currently Overvalued.
Does Astec Lifesciences Limited pay dividends?
Astec Lifesciences Limited pays a Annually dividend of ₹1.5 which represents an annual dividend yield of N/A. See more information on Astec Lifesciences Limited dividends here
What is Astec Lifesciences Limited’s EPS estimate?
Astec Lifesciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Astec Lifesciences Limited have?
Astec Lifesciences Limited has 22,282,820 shares outstanding.
What happened to Astec Lifesciences Limited’s price movement after its last earnings report?
Astec Lifesciences Limited reported an EPS of -₹3.5 in its last earnings report, missing expectations of ₹0.5. Following the earnings report the stock price went up 3.668%.
Which hedge fund is a major shareholder of Astec Lifesciences Limited?
Currently, no hedge funds are holding shares in IN:ASTEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Astec Lifesciences Limited
Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maize, as well as grains, such as barley, rice, and wheat; post-harvest drench; and food additive and wood preservative. It also provides herbicides, insecticides, and specialty chemical products. The company also exports its products. The company was incorporated in 1994 and is based in Mumbai, India. Astec LifeSciences Limited is a subsidiary of Godrej Agrovet Limited.
Technical Analysis
Heranba Industries Limited
―
IG Petrochemicals Ltd.
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Punjab Chemicals & Crop Protection Ltd.
―
Uniphos Enterprises Limited
―